Compare Incyte Corporation (INCY) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs United Parcel Service Inc — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while United Parcel Service Inc trades at $113.31 (market cap $96.18B). The key difference: United Parcel Service Inc is far larger — about 4.2× Incyte Corporation's market cap, and United Parcel Service Inc pays a 5.8% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | UPS | |
|---|---|---|
Market Cap | $23.11B | $96.18B |
Sector | Health | Industrials |
52-Week High | $118.52 | $120.00 |
52-Week Low | $67.38 | $82.58 |
Enterprise Value | $19.13B | $119.04B |
Volume | — | 2,288,643 |
Dividend Yield | — | 5.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
UPS stock trades at $112.97, down 4.03% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company maintains strong profitability with 33.41% ROE and 5.94% net margin, though revenue has declined from $100.3B in 2022 to $88.7B in 2025. Recent quarters show consistent earnings beats, with Q2 2026 results expected on July 28, 2026. Analyst sentiment is divided with 42% buy ratings and consensus price target of $112.
UPS faces near-term headwinds from revenue pressure and Amazon's logistics expansion, but cost-cutting initiatives and healthcare investments provide growth catalysts. The stock's current valuation at 19x P/E appears reasonable given strong cash flow generation. Key risks include competitive threats and economic sensitivity, while dividend sustainability remains a focus with the $1.64 per share payout.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
